Targeting Amyloid

Aducanumab results showed removal of amyloid plaques in patients with Alzheimer's disease published in Nature.

Read more

To confirm the early findings on clinical stabilization, large-scale Phase 3 clinical trials of aducanumab (ENGAGE and EMERGE) are now underway at more than 300 study sites across 20 countries in North America, Europe and Asia, and these will assess the efficacy and safety of the drug in approximately 2,700 people with early Alzheimer’s disease.

Aducanumab ¦ ALZFORUM

Aducanumab study ENGAGE
Aducanumab study EMERGE